International law firm Osborne Clarke has advised a transatlantic syndicate of top-tier life sciences investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital and Fonds de solidarité FTQ in US$13.6 million funding round. The seed round was also supported by Novateur Ventures and the Harrington Discovery Institute/University Health Holdings.
Founded in 2021 and consisting of sister companies based in Cambridge, UK and in Montreal, Canada, Epitopea is a global biotechnology company developing transformation immunotherapies to treat cancer by exploiting a new class of untapped tumour-specific antigens (TSAs). The funding will leverage Epitopea’s ground-breaking CryptigenTM approach to create transformational immunotherapies that target broad cancer patient populations in both solid and haematological cancers with minimal side effects.
The seed financing will be used to build the company’s executive team, advance further research on this new class of antigens, and catalyse their translation into novel cancer immunotherapeutics, including therapeutic vaccines, cell therapies, and TCR-based biologics.
Osborne Clarke’s Corporate team is considered a go-to practice for many companies in the life sciences and healthcare sector. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.